Treatment of endometriosis by vaginal administration of gestrinone.
The effectiveness and acceptability of gestrinone administered by vaginal route was evaluated in a group of 110 patients with endometriosis. Patients were divided into four groups. The first three groups were treated by vaginal route. Group I (n = 17) received two 2.5-mg tablets weekly; group II (n = 31) received three 2.5-mg tablets weekly; group III (n = 35) received two 5.0-mg tablets weekly. Group IV consisted of 27 patients who received 2.5 mg of gestrinone orally twice weekly. Ninety-eight women completed the 6- to 8-month treatment period. Amenorrhea developed in all treatment groups, including group I (34%). The disappearance of both dyspareunia and dysmenorrhea occurred in most patients in all treatment groups soon after the second month of therapy. Patients treated by vaginal route had significantly less seborrhea and acne than those treated by oral route. Weight gain was also significantly less in vaginally treated women than in those treated orally. Pregnancy rate following discontinuation was not significantly different for the various groups.
Coutinho
E M
EM
Maternidade Climerio de Oliveira, Federal University of Bahia, Salvador, Brazil.
Azadian-Boulanger
G
G
D000284:Administration, Oral; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D005867:Gestrinone / Q000008:administration & dosage*; D006801:Humans; D009651:Norpregnatrienes / Q000008:administration & dosage*; D013607:Tablets; D014621:Vagina
D009651:Norpregnatrienes; D013607:Tablets; D005867:Gestrinone